Prognostic Cancer ModelChemotherapyNutrition Related Cancer
Study summary
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.
Eligibility
Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria:
* 1\. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
* 2\. Visit our center with complete medical records and pathological information;
* 3\. Colorectal cancer patients diagnosed between 2013 and 2023.
Exclusion Criteria:
* 1\. The patient has other colorectal malignancies other than adenocarcinoma;
* 2\. Malignant tumors adjacent to organs invading the colon and rectum;
* 3\. Malignant tumors from distant organs metastasize to the colon and rectum;
* 4\. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.
Primary outcome measure(s)
overall survival — from date of diagnosis until the date of death from any cause, assessed up to 120 months to dead or lost to follow
DFS — from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months disease-free survival
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.